<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33263951</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>TDP-43 as structure-based biomarker in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>271</StartPage><EndPage>277</EndPage><MedlinePgn>271-277</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51256</ELocationID><Abstract><AbstractText>Pathologic alterations of Transactivation response DNA-binding protein 43 kilo Dalton (TDP-43) are a major hallmark of amyotrophic lateral sclerosis (ALS). In this pilot study, we analyzed the secondary structure distribution of TDP-43 in cerebrospinal fluid of ALS patients (n&#xa0;=&#xa0;36) compared to Parkinson&#xb4;s disease patients (PD; n&#xa0;=&#xa0;30) and further controls (Ctrl; n&#xa0;=&#xa0;24) using the immuno-infrared sensor technology. ALS patients could be discriminated from PD and Ctrl with a sensitivity/specificity of 89 %/77 % and 89 %/83 %, respectively. Our findings demonstrate that TDP-43 misfolding measured by the immuno-infrared sensor technology has the potential to serve as a biomarker candidate for ALS.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beyer</LastName><ForeName>L&#xe9;on</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5889-6044</Identifier><AffiliationInfo><Affiliation>Center for Protein Diagnostics (ProDi), Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Biology and Biotechnology, Department of Biophysics, Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nther</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Jan Christoph</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Medicine G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klebe</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagenacker</LastName><ForeName>Tim</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3631-3450</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lingor</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9362-7096</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Medicine G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Klinikum rechts der Isar, Department of Neurology, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biesalski</LastName><ForeName>Anne-Sophie</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0002-1288-884X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7364-7791</Identifier><AffiliationInfo><Affiliation>Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Rostock/Greifswald, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nabers</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Protein Diagnostics (ProDi), Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Biology and Biotechnology, Department of Biophysics, Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gold</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Protein Diagnostics (ProDi), Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xf6;nges</LastName><ForeName>Lars</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-6621-144X</Identifier><AffiliationInfo><Affiliation>Center for Protein Diagnostics (ProDi), Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerwert</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Protein Diagnostics (ProDi), Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Biology and Biotechnology, Department of Biophysics, Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013055" MajorTopicYN="N">Spectrophotometry, Infrared</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>P.L and L.T. are inventors on a patent for the use of Fasudil for the treatment of Amyotrophic lateral sclerosis (EP 2825175 B1, US 9.980,972 B2). All other authors declare that there are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>2</Day><Hour>12</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33263951</ArticleId><ArticleId IdType="pmc">PMC7818221</ArticleId><ArticleId IdType="doi">10.1002/acn3.51256</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gagliardi D, Meneri M, Saccomanno D, et al. Diagnostic and prognostic role of blood and cerebrospinal fluid and blood neurofilaments in amyotrophic lateral sclerosis: a review of the literature. Int J Mol Sci 2019;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6747516</ArticleId><ArticleId IdType="pubmed">31450699</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder V, Gregory JM, Barria MA, et al. TDP&#x2010;43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta&#x2010;analysis. BMC Neurol 2018;18:90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027783</ArticleId><ArticleId IdType="pubmed">29954341</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (New York, NY) 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R, Neumann M. TDP&#x2010;43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010;9:995&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabers A, Ollesch J, Schartner J, et al. Amyloid&#x2010;&#x3b2;&#x2010;secondary structure distribution in cerebrospinal fluid and blood measured by an immuno&#x2010;infrared&#x2010;sensor: a biomarker candidate for Alzheimer's disease. Anal Chem 2016;88:2755&#x2013;2762.</Citation><ArticleIdList><ArticleId IdType="pubmed">26828829</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabers A, Perna L, Lange J, et al. Amyloid blood biomarker detects Alzheimer's disease. EMBO Mol Med (2018;10:2&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5938617</ArticleId><ArticleId IdType="pubmed">29626112</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabers A, Hafermann H, Wiltfang J, et al. A&#x3b2; and tau structure&#x2010;based biomarkers for a blood&#x2010; and CSF&#x2010;based two&#x2010;step recruitment strategy to identify patients with dementia due to Alzheimer's disease. Alzheimer's Dementia (Amsterdam, Netherlands) 2019;11:257&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416642</ArticleId><ArticleId IdType="pubmed">30911600</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabers A, Ollesch J, Schartner J, et al. An infrared sensor analysing label&#x2010;free the secondary structure of the Abeta peptide in presence of complex fluids. J Biophotonics 2016;9:224&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">25808829</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocker H, Nabers A, Perna L, et al. Prediction of Alzheimer's disease diagnosis within 14 years through A&#x3b2; misfolding in blood plasma compared to APOE4 status, and other risk factors. Alzheimers Dement 2020;16:283&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">31611055</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008;119:497&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, et al. Molecular mechanisms of TDP&#x2010;43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci 2019;12:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenther EL, Ge P, Trinh H, et al. Atomic&#x2010;level evidence for packing and positional amyloid polymorphism by segment from TDP&#x2010;43 RRM2. Nat Struct Mol Biol 2018;25:311&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6056015</ArticleId><ArticleId IdType="pubmed">29531287</ArticleId></ArticleIdList></Reference><Reference><Citation>Noto Y&#x2010;I, Shibuya K, Sato Y, et al. Elevated CSF TDP&#x2010;43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value. Amyotroph Lateral Scler 2011;12:140&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">21126161</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai T, Tokuda T, Ishigami N, et al. Increased TDP&#x2010;43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol 2009;117:55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">18989684</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>